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Creation of an intact skin water barrier, a prerequisite for life
on dry land, requires the lipoxygenase-catalyzed oxidation of
the essential fatty acid linoleate, which is esterified to the-hy-
droxyl of an epidermis-specific ceramide. Oxidation of the lino-
leatemoiety by lipoxygenases is proposed to facilitate enzymatic
cleavage of the ester bond, releasing free -hydroxyceramide
for covalent binding to protein, thus forming the corneocyte
lipid envelope, a key component of the epidermal barrier.
Herein, we report the transformations of esterified linoleate
proceed beyond the initial steps of oxidation and epoxyalcohol
synthesis catalyzed by the consecutive actions of 12R-LOX and
epidermal LOX3. Themajor end product in human and porcine
epidermis is a trihydroxy derivative, formed with a specificity
that implicates participation of an epoxide hydrolase in convert-
ing epoxyalcohol to triol. Of the 16 possible triols arising from
hydrolysis of 9,10-epoxy-13-hydroxy-octadecenoates, using
LC-MS and chiral analyses, we identify and quantify specifically
9R,10S,13R-trihydroxy-11E-octadecenoate as the single major
triol esterified in porcine epidermis and the same isomer with
lesser amounts of its 10Rdiastereomer inhumanepidermis. The
9R,10S,13R-triol is formed by SN2 hydrolysis of the 9R,10R-ep-
oxy-13R-hydroxy-octadecenoate product of the LOX enzymes,
a reaction specificity characteristic of epoxide hydrolase. The
high polarity of triol over the primary linoleate products
enhances the concept that the oxidations disrupt corneocyte
membrane lipids, promoting release of free-hydroxyceramide
for covalent binding to protein and sealing of the waterproof
barrier.
Construction of the mammalian epidermal water barrier
involves the coordinated actions of many gene products, the
inactivating mutations of which lead to the fish skin symptoms
of congenital ichthyosis in affected human families (1) and neo-
natal lethality in mice due to the transepidermal water loss (2).
The genetic evidence identifies the enzymes 12R-lipoxygenase
(12R-LOX)4 and epidermal lipoxygenase-3 (eLOX3) as among
those critical for construction of an intact epidermal water bar-
rier (3–7). Deletion of either enzyme results in a structural
defect in the epidermal barrier, namely50–99% reduction in
omega-hydroxyceramide (OS) covalently bound to protein and
the consequent absence or disruption of the corneocyte lipid
envelope (CLE) (7, 8). The CLE is considered to be an integral
component of the barrier, being a critical intermediary between
polymerized protein and extracellular lamellar lipids (Fig. 1A)
(9, 10). A marked reduction in covalently bound ceramides is
also a feature of the barrier defect in essential fatty acid (EFA)
deficiency (11).
Starting from the very discovery of essential fatty acids, it was
recognized that linoleic acid plays a role in sealing themamma-
lian epidermal water barrier (12, 13). A classic symptom of EFA
deficiency is transepidermal water loss with development of a
scaly skin, the latter in compensation or response to the barrier
defect. Topical application of linoleate restores barrier function
and corrects the scaly skin phenotype (14, 15). Linoleic acid is
by far the most abundant polyunsaturated fatty acid present in
the mammalian outer epidermis (16). It is almost exclusively
esterified in epidermis-specific ceramides, glucosylO-acyl-cer-
amide, and its deglucosylated product, O-acyl-ceramide, also
known as ceramide EOS, esterified omega-hydroxyacyl-sphin-
gosine (Fig. 1B) (17–19). The linoleate-containing EOS cer-
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vitro, and wild-type pig and mouse epidermis contain trace
quantities of specific 12R-LOX and eLOX3 products esterified
in the EOS ceramide (Scheme 1A); these oxidized linoleates are
absent in the 12R-LOX knock-out (8). Taking all the informa-
tion on EFA, LOX enzymes, and the consequences of the gene
knock-outs together, Zheng et al. (8) proposed a model to
explain their cooperation in forming the epidermal barrier. The
concept is that LOX activity is required to oxidize the linoleate
in EOS ceramide, which in turn is required to facilitate esterase-
catalyzed cleavage of the (oxidized) fatty acid, thus converting
EOS to OS, the -hydroxyceramide used to bond to polymer-
ized protein and thus construct the CLE (Fig. 1B). In EFA defi-
ciency, oleate, which is not a LOX substrate, replaces linoleate
in EOS (20, 21); therefore, the fatty acid cannot be oxidized and
cannot be cleaved, leading to a reduction in the building blocks
(OS ceramide) available for construction of the CLE. In the
LOX knock-outs, the enzyme(s) catalyzing the oxidation are
absent, with similar functional consequences.
This study, to analyze epidermis for esterified trihydroxy-
linoleate species, was prompted by our difficulties in detecting
the initial oxidized ceramide species in human epidermis that
we had found earlier inmouse and pig skin (Scheme 1A) (8).We
hypothesized linoleate oxidation in the epidermis might pro-
ceed further than the two steps catalyzed by 12R-LOX and
eLOX3 and that the trihydroxy hydrolysis products of these
intermediates might be the final oxidized product of the path-
way (Scheme 1B).We therefore sought to identify andmeasure
normal human and pig epidermis for the presence of linoleate
triols derived via 12R-LOX/eLOX3 catalysis.
In itself the characterization of trihydroxy-linoleates is chal-
lenging. The analyses are complicated by the number of possi-
ble isomers, the symmetry of many of the triol structures, by
their subtle differences in mobility in most chromatographic
systems, and in some cases by the poor chromatographic per-
formance, with the tailing of one peak into another. To circum-
vent these potential issues, we developed a new method appli-
cable to fatty acid triol analysis, encompassing both improved
chromatographic resolution with highly sensitive detection of
the pentafluorobenzyl (PFB) ester derivative by LC-MS. In
addition to the analysis of epidermal linoleate triols, the new
methodology presented here has potential application to anal-
ysis of triols in plant embryogenesis and development (22), in
plant defense (23, 24), and in commercial flavoring (as fatty acid
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FIGURE 1. Structures of the epidermal water barrier and formation of
the CLE. A, electron micrograph of the epidermal barrier with the parts
illustrated in schematic style. In the barrier layer of the epidermis the
corneocytes aremelded together by fusion of three substructures: polym-
erized protein forming the corneocyte envelope (CE) on the periphery of
each cell, extracellular lamellar lipids between cells, and the monolayer of
covalently bound ceramides and fatty acids, the CLE, covering the corneo-
cyte envelope and forming a scaffold for the lamellar lipids. B, our working
hypothesis (8) entails LOX-catalyzed oxidation of the linoleate in EOS cer-
amide, facilitating hydrolysis of the ester bond, freeing OS ceramide for
coupling to the corneocyte envelope protein by transglutaminase
(TGase), thus forming the CLE. The electron micrograph is from Ref. 66
with permission.
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SCHEME 1. A, partial structures showing reaction of 12R-LOX and eLOX3 on
linoleate ceramide esters. B, potential transformation of linoleate epoxyalco-
hol to triols.
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triols are bitter-tasting constituents of foodstuffs and beer (25–
28)). The methodology is also adaptable for analysis of the
arachidonate triols implicated as an arterial endothelium-de-
rived hyperpolarizing factor (29, 30) and the 12-LOX-derived
trioxilins (31, 32).
Experimental Procedures
Reagents—Linoleic acid was purchased from Nu-Chek Prep
Inc. (Elysian, MN); [9,10,12,13-2H4]linoleic acid was from Cay-
man Chemical (Ann Arbor, MI), and [1-14C]linoleic acid was
from PerkinElmer Life Sciences Radiochemicals. 9S-HPODE
was prepared using the 9S-LOX in potato homogenate as
described previously (33), and 9R-HPODE using Anabaena
9R-LOX (34). Epoxyalcohol and triol derivatives of 9-hydroper-
oxy-linoleic acid were prepared as described previously (35).
Ceramide-EOS was a generous gift from Evonik. Pentafluoro-
benzyl bromide (PFBBr), p-toluene sulfonic acid, pyridinium
p-toluenesulfonate, diisopropylethylamine, 2,2-dimethoxypro-
pane (DMP), trimethylamine, and N,O-bis(trimethylsilyl)trif-
luoroacetamide were obtained from (Sigma).
Preparation of aMix of Eight Deuterated Triols by Autoxida-
tion of [2H4]Linoleic Acid—Deuterated linoleic acid (5 mg) was
methylated with diazomethane, dissolved in ethanol (EtOH)
with 10% -tocopherol, transferred to a 20-ml vial and taken to
dryness, and then left in an atmosphere of oxygen for 1 week at
room temperature. The autoxidized sample was subsequently
hydrolyzed to the free acids by addition of 2 ml of methanol
(MeOH), 200 l of dichloromethane (DCM), and 2 ml of 1 M
KOH and incubated for 40min at room temperature. The solu-
tion was acidified to pH 5 and extracted by vigorous mixing
with 3ml of ice-coldDCM; the organic phase was washed twice
with ice-cold water, transferred to a fresh vial, dried under N2,
and dissolved in 25 l of MeOH. Five ml of 0.1 M K2HPO4 and
200 l of hematin (10 mg/ml in DMSO) were added and left to
react for 15 min at room temperature. To hydrolyze the result-
ing allylic epoxides to triols, the sample was acidified to pH 3
and left standing for 1 h at room temperature. The sample was
then cooled on ice and extracted with 5 ml of ethyl acetate,
which was washed twice with cold water, transferred to a fresh
vial, dried under N2, and dissolved in 1.25 ml of ethyl acetate.
Hexane (3.75 ml) was added immediately before loading onto a
0.5 g of Bond-Elut silica cartridge pre-conditioned with 25%
ethyl acetate in hexane. After washing the columnwith an addi-
tional 10 ml of 25% ethyl acetate in hexane and 10 ml of 100%
ethyl acetate, the triol products were eluted with 5% MeOH in
ethyl acetate (10 ml). The d4-triols were subsequently purified
as a group by reversed phase-HPLC employing a Waters Sym-
metry C18 column (250  4.6 mm) eluted isocratically with
methanol/water/acetic acid (70:30:0.01) at 1 ml/min. The
205-nm absorbing peaks in the triol region of the chromato-
gram at 8–10 min of retention time were collected and used
without further purification. This mixture of d4-triols was dif-
ficult to quantify because of the absence of weighed triol stan-
dards for comparison and also the multiple overlapping peaks
on reversed phase-HPLC and SP-HPLC chromatograms. The
yield was estimated as100 g of the d4-triol mixture.
Preparation of Deuterated 9-HODE, Epoxyalcohol, and Tri-
ols from [2H4,14C]Linoleic Acid—Deuterated linoleic acid (1
mg, 3.57mol)wasmixedwith [1-14C]linoleic acid (1Ci), and
a small aliquot was counted. Subsequent quantitation of
d4-products was based on the known 14C-specific activity
(which for the conjugated diene-containing products
9-HPODEand9-HODEwas checked byUV spectroscopy). The
[2H4,14C]linoleic acid was reacted with Anabaena 9R-LOX
(34), and the 9R-HPODEproductwas purified by SP-HPLCand
quantified by UV spectroscopy, and an aliquot was counted.
The 9R-HPODE (0.7 mg) was then reacted with hematin as
above, and the epoxyalcohols and other products were sepa-
rated by SP-HPLC (35); aliquots of the 2H4/14C-labeled
9-HODE and 9R,10R-trans-epoxy-13R-hydroxy epoxyalcohol
were quantified by liquid scintillation counting. The deuterated
9-HODE and one-third of the d4-epoxyalcohol were kept for
use in quantitative assays. The remainder of the epoxyalcohol
was treated with 200 l of 1% acetic acid in CH3CN/H2O (1:1
v/v) for 1 h at room temperature, then the solvent was evapo-
rated using a stream of nitrogen. The resulting 2H4/14C-labeled
triol isomers were partially resolved at long retention times
(120 min) on a Waters symmetry column (25  0.46 cm)
using a solvent of CH3CN/H2O/HAc (30:70:0.01 v/v/v) run at
0.5 ml/min with UV detection at 205 nm. A fraction containing
a mixture of mainly triols 3 and 4 (as assigned later) in equal
proportions was identified by LC-MS and quantified by liquid
scintillation counting. (The fraction containing d4-triols 3 and
4 was not further purified because of the limited quantity avail-
able and the lack of a suitable chromatographic system for their
separation.) For quantitative analysis of triol- 3 in epidermis,
the samples were spiked with 0.2 nmol of themixture (and thus
0.1 nmol of d4-triol-3 added).
Preparation of Epidermis—Pig skin was obtained within 30
min of euthanasia from animals used in unrelated experiments
approved by the Institutional Animal Care andUseCommittee.
Sections of pig skin (10  10 cm) were immersed in 65 °C
phosphate-buffered saline (PBS) for 2min, and then the epider-
mis was separated from the dermis using tweezers. Normal
human skin was provided by healthy donors (female; 29–53
years old; African American and Caucasian), undergoing
abdominoplastic surgery, and delivered to our laboratory
within 1 h of the operation. Informed consent was obtained
from each patient, and the clinical research ethics committee of
Vanderbilt University reviewed and approved the study. The
human epidermis (10  10 cm) was isolated after treating
with 2.0 mg/ml Dispase II (Roche Applied Science) in 50 mM
HEPES, pH 7.4, at 4 °C overnight.
Lipid Extraction—The epidermis was blotted dry, weighed,
then homogenized in chloroform/methanolmixtures (1:1, v/v).
The organic layer was separated from the protein pellet by cen-
trifugation. Thiswas repeated three times. The lipid extractwas
dried under a stream of N2 and then redissolved in chloroform.
The lipid extract was loaded onto a pre-equilibrated solid phase
silica column in chloroform/hexane (1:1, v/v) (HF Bond Elut SI,
Agilent), washed with chloroform/hexane (1:1, v/v), and eluted
with chloroform and chloroform/methanol (9:1, v/v); the frac-
tions were taken to dryness, and each was redissolved in 1ml of
CHCl3 for further analysis.
Linoleate Triols in Skin Barrier Function
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LC-MS Screening of Epidermal Extracts for Linoleate
and Linoleate Triol-containing Ceramides—Methanol/CHCl3
extracts were analyzed using an Advantage 5-m silica column
(250 4.6 mm) run with gradient elution of hexane/IPA/HAc
(95:5:0.1) to hexane/IPA/HAc (75:25:0.1) over 30 min using a
Waters Alliance 2690 HPLC system coupled to a TSQ Vantage
mass spectrometer (Thermo Scientific) with instrument condi-
tions as reported previously (8). The spectra were obtained in
full scan mode between the mass range m/z 650–1350 moni-
toring in ve APCI mode. SIM was carried out in the same
system in -veAPCImode to allowdetection of the daughter free
fatty acids.
Identification of Free and Esterified Triols in Epidermis—For
analysis of the linoleate triol isomeric composition, aliquots of
the combined CHCl3 and 10%MeOH in CHCl3 eluates (corre-
sponding to 10 mg of epidermis extracted) containing free
and esterified fatty acid triols were spiked with the d4-linoleate
triolmixture (40 ng) and processed in one of threeways (illus-
trated in supplemental Fig. S1). For analysis of free triols, the
sample is initially subjected to a Bligh andDyer extraction using
pH 8 aqueous phase; the ionized trihydroxy fatty acids remain
in the aqueous phase while the neutral and non-polar lipids
partition into the CHCl3 phase and are discarded; extraction
with theoretical lower phase is repeated and the CHCl3 again
discarded. After evaporation of the aqueous phase to half vol-
ume to remove residual CHCl3 and most of the MeOH, the
sample is diluted with water, acidified to pH 6 (mildly acidic, to
avoid acid hydrolysis of epoxyalcohols), and loaded onto a 1-cc/
30-mg Oasis HLB cartridge (Waters). After elution of salts and
aqueous-soluble impurities using water/MeOH (9:1), the triols
are recovered by elutionwithwater/MeOH (1:9). For analysis of
esterified triols, the samples from the initial silica cartridge
fractionationwere treatedwithKOHovernight to release ester-
ified fatty acids (total volume of 500 l consisting of 100 l of
10% MeOH in CHCl3 epidermal extract, 275 l of MeOH, and
125 l of 2 M KOH in 20% water in MeOH, final KOH concen-
tration, 0.5 M). The de-esterified products were then extracted
using the Bligh and Dyer proportions of CHCl3, MeOH, and
aqueous phase (still containing theKOH)with theCHCl3 phase
discarded; extraction was repeated using theoretical lower
phase. After concentration of the aqueous phase to about half-
volume, the sample is diluted with water and carefully acidified
to pH 6 for Oasis HLB extraction as for the free triols, or alter-
natively, the sample is acidified to pH 3 and allowed to stand at
room temperature for 1 h (to permit acid hydrolysis of labile
epoxyalcohols) and then extracted on the Oasis HLB cartridge.
All samples are converted to the PFB ester DMP acetonide
derivative for LC-MS,GC-MS, or chiralHPLC-UVanalysis. For
GC-MS and chiral HPLC analyses of individual triols, the
scheme was repeated using larger aliquots of epidermis extract
and without addition of the d4-triol mixture.
Quantitation of 9-HODE, Epoxyalcohol, and Triols in the
Epidermis—To optimize recovery of the acid-sensitive epoxy-
alcohol, the extracts were kept neutral or alkaline throughout
the analytical procedure. The scheme is summarized in supple-
mental Fig. S2. Aliquots (2%, corresponding to an extract of
10mg of epidermis) of the combinedCHCl3 and 10%MeOH/
CHCl3 fractions from the open-bed silica column (and for free
triol analysis also combined with the MeOH silica column elu-
ate) were spiked with 0.1 nmol of d4–9-HODE, 0.1 nmol of the
d4-epoxyalcohol (9R,10R-trans-epoxy-13R-hydroxy-octadec-
11E-enoic acid), and 0.2 nmol of the d4-triol (composed of
equal proportions of triols-3 and -4). For analysis of esterified
products, the samples were treated with KOH overnight as
described above and then extracted twice using the Bligh and
Dyer proportions of CHCl3,MeOH, and (KOH) aqueous phase.
After concentration of the aqueous phase (still containing the
KOH) to approximately one-third volume (0.5 ml) and addi-
tion of 2 ml of water, the alkaline solution was loaded onto a
1-cc/30-mgOasis HLB cartridge that was pre-equilibratedwith
MeOH then water; 2 ml of water, the alkaline solution was
loaded onto a 1 ml/30 mg of Oasis HLB cartridge that was
pre-equilibrated with MeOH then water; after washing with
water until a neutral reaction, the products were eluted with 1
ml of EtOAc. The free product levels were quantified in essen-
tially the same way except omitting the KOH hydrolysis and
substituting 0.1 M K2HPO4, pH 8.5, for the Bligh and Dyer
extraction and HLB extraction steps. Although the samples
were loaded onto the HLB cartridge in alkaline solution, recov-
eries of the linoleate derivatives were quantitative.
Derivatization Procedures—PFB esters were prepared by dis-
solving the d4 standards or human skin extracts in 20 l of
acetonitrile, 20 l of PFBBr in acetonitrile (1:19, v/v), and 20 l
of diisopropylethylamine in acetonitrile (1:9, v/v). The solution
was incubated at room temperature under argon for 30min and
then evaporated to dryness under nitrogen. Acetonide deriva-
tives of the triols were prepared by addition of DMP/acetone
(1:1) containing 1 mM p-toluene sulfonic acid to the dry PFBBr
ester derivatives (reaction was complete within 5 min at room
temperature); the acid was then neutralized using an equal vol-
ume of triethylamine (1.5 mM) in DCM, and the sample was
taken to dryness. Alternatively, the DMP derivative was pre-
pared using 20 l of 1 mM pyridinium p-toluenesulfonate in
acetone/DMP (1:1 by volume) for 30 min at room temperature
and then directly taken to dryness (as neutralization is not
required using the pyridinium salt).
LC-MSAnalyses—PFB ester DMP derivatives of the linoleate
triols were detected by APCI-LC-MS using a TSQ Vantage
instrument (Thermo Scientific), Waters Alliance 2690 HPLC
system, and a Thomson Advantage 150A 5-m silica column
(250 4.6 mm) with a solvent of hexane/IPA (100:1, v/v) and a
flow rate of 1 ml/min. The APCI vaporizer temperature was set
to 300 °C, and the heated electrospray ionization probe temper-
ature was set to 150 °Cwith selected ionmonitoring of negative
ions atm/z 369 for the unlabeled triol derivatives andm/z 373
for the d4 internal standard. Quantitation of 9-HODE used the
same equipment with an SP-HPLC solvent of hexane/IPA (100:
0.5, v/v) and monitoring m/z 295 and 299. For epoxyalcohol
quantitation the SP-HPLC solvent was changed to hexane/IPA
(100:1.5, v/v), and the ions monitored werem/z 311 and 315.
GC-MS—Analysis of the major epidermal triol was carried
out on the PFB ester DMP acetonide and trimethylsilyl ether
derivative using an Agilent/J and W DB-5MS column (25 m
0.2 mm, 0.33-m film) in an Agilent 6890 GC/5973 MSD
instrument operated in the electron ionization mode (ion
Linoleate Triols in Skin Barrier Function
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source temperature 250 °C, electron energy 70 eV) set to full
scans fromm/z 50 to 700.
Chiral Analysis of Epidermal Products—Chiral HPLC analy-
sis of linoleate triols was conducted on the PFB ester DMP
derivatives using a Chiralpak 5-m AD-H column, 150  2.1
mm (Chiral Technologies, Exton, PA), a solvent of hexane/
MeOH (100:2), and a flow rate of 0.25 ml/min, with LC-MS
monitoring of m/z 369 in the APCI mode as described above.
Racemic triol standardswere prepared from racemic 9-HPODE
and standards of known chirality from 9S-HPODE using the
methods previously described (35). There was sufficient of the
main epidermal triol of pig epidermis that the chiral HPLC
analysis did not require use of LC-MS for sensitivity; the anal-
ysis was preformed with UV detection of the PFB DMP deriva-
tive at 205 nm.
For chiral analysis of 9-HODE and the epoxyalcohol 9,10-
trans-epoxy-13-hydroxy-octadec-11E-enoic acid esterified in
human epidermis, 20% of extracts of 10 10 cm pieces of epi-
dermis were taken through the extraction procedure outlined
above (except with no added d4 standards and using a 4-fold
increase in solvent volumes for the KOH hydrolysis and Bligh
and Dyer extraction). After application of3 ml of KOH solu-
tion to the 30-mg Oasis HLB cartridge, elution with EtOAc (1
ml), and subsequent preparation of the PFB esters, samples
were subjected to SP-HPLC using a Thomson silica column
with a solvent of hexane/IPA (100:1.5 v/v) run at 0.5 ml/min
with UVmonitoring at 205, 220, 235, and 270 nm and simulta-
neous recording of UV spectra. The easily visible peak of
9-HODE (attaining a peak absorbance of300–400 mAU and
preceded by equally prominent peaks of 12-HETE and
13-HODE PFB esters) was collected at an 10-min retention
time, and the single prominent peak of epoxyalcohol PFB ester
(visible most prominently at 205 nm) was collected at16 min
retention time. Chiral analysis of the purified 9-HODE PFB
ester used a Chiralcel OD-H column (25 0.46 cm), a solvent
of hexane/IPA (100:5 v/v), and a flow rate of 1 ml/min; the
enantiomers eluted at 9.1 min (9S) and 10.5 min (9R) and were
detected by UV monitoring at 235 nm. Chiral analysis of the
purified PFB ester of the epoxyalcohol (9,10-trans-epoxy-13-
hydroxy-octadec-11E-enoic acid) fromhuman skin employed a
Chiralcel OJ column (25  0.46 cm) with a solvent of hexane/
IPA 100:10 (v/v) and a flow rate of 1 ml/min with LC-MS
(APCI) monitoring of m/z 369; the enantiomers eluted at 7.6
(9S,10S,13S configuration) and 8.8 min (9R,10R,13R) as estab-
lished using epoxyalcohol standards prepared from 9RS-
HPODE and 9S-HPODE.
Quantitative Analysis of Esterified Arachidonic Acid (AA),
Linoleic Acid (LA), and -Linolenic Acid (-LNA) in the
Epidermis—The esterified AA, LA, and -LNA in the epider-
mal ceramide fractions from the initial silica column were ana-
lyzed using d4-LA as internal standard: 1% percent (10 l from
1ml) of the 10%MeOH inCHCl3 andCHCl3 fractions in 1.5-ml
Eppendorf tubes was treated with 100 l of 1 M KOH in 20%
water in MeOH under argon at room temperature overnight.
d4-LA (10 l, 10 g) was added, and then the samples were
acidified to pH 4 by addition of 625l of 1 M acetic acid, and the
free fatty acids were extracted with 0.75 ml of 10% ethyl acetate
in hexane. The solution was taken to dryness and converted to
the PFB ester for LC-MS analysis; the PFB esters were dissolved
in 1 ml of hexane and 1% injected. PFB esters of AA, LA, and
-LNA in the epidermis were detected using the TSQ Vantage
instrument coupled to a Waters Acquity UPLC system with a
Phenomenex Kinetex 2.6 -m C18 column (100  3 mm), a
solvent of MeOH/H2O/HAc (95:5:0.01, v/v/v), and a flow rate
of 0.5 ml/min. Negative ions were monitored at m/z 277 (for
-LNA),m/z 279 (LA),m/z 283 (d4-LA), andm/z 303 (AA).
Results
LC-MS Detection of Epidermal Ceramides Containing Lino-
leate Triols—Human epidermal extracts were screened for the
possible occurrence of oxidized ceramides using straight-phase
HPLC separation of the ceramide esters with LC-MS detection
of either positive or negative ions. Fig. 2A illustrates an
extracted ion chromatogram of positive ions in the mass range
m/z 950–1350. This mass range encompasses the acyl-cer-
amides (EOS-related) and excludes lower weight species such
as typical ceramides and phospholipids. The ceramides with
unoxidized fatty acid esters eluted early in this SP-HPLC sys-
tem and can be identified as EOS, EOP, and EOH. The polar
glucosyl ceramides eluted late in the chromatogram and can be
identified as Glc-EOS, Glc-EOP, and Glc-EOH (data not
shown). Fig. 2B shows themass spectrum of the peak of interest
eluting at 20 min; the masses correspond primarily to cer-
amides with C32 and C34 N-linked very long chain fatty acids
coupled by ester linkage to esterified trihydroxy-linoleates. In-
source fragmentation results in several characteristic ions, for
example m/z 1054 and 1072 represent the [M  2H2O] and
[M  H2O] ions of the C32 species, and m/z 1082 and 1100
represent the [M  2H2O] and [M  H2O] of the C34 cer-
amide. To confirm the structural assignment of these cer-
amides, an SIM method was developed to monitor the specific
parent to daughter transition for the C32 carbon molecule of
each species. Fig. 2C, recorded in the negative ionmode for fatty
acid detection, illustrates the SIM chromatogram for the fol-
lowing species: C32 EOS,m/z 1075–279 [M Cl], C32 EOS-
tri-OH,m/z 1149–329 [MHCH3CO2H], andm/z 1237–
279 [M Cl], withm/z 279 and 329 confirming the presence
of linoleate and linoleate triol, respectively. Very similar results
were obtained in analysis of porcine epidermis (data not
shown).
LC-MS Analysis of Linoleate Triols as the PFB Ester DMP
Derivative—Having detected epidermal ceramide species con-
taining esterified linoleate triols, we developedmethods for the
analysis and quantitation of individual trihydroxy isomers. As
outlined under “Experimental Procedures,” the authentic trihy-
droxy-linoleate standards were prepared by hematin treatment
of 9-HPODE followed by separation of the two major 9,10-
trans-epoxy-13-hydroxy epoxyalcohol diastereomers and their
acid hydrolysis to give four triols from each (Fig. 3A) (35). The
first of the two epoxyalcohols to elute from SP-HPLC, 9R,10R-
epoxy-13R-hydroxy-octadec-11E-enoic acid, is hydrolyzed
under mild acidic conditions to the four triols designated here
as 1–4, and the second epoxyalcohol diastereomer (9R,10R-
epoxy-13S-hydroxy) gives triols 5–8 (Fig. 3B). The structure
and stereochemistry of all these products were assigned partly
from the known configuration of the 9-HPODE starting mate-
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rial. The epoxyalcohols were then characterized by mass spec-
trometry and proton NMR, plus circular dichroism to establish
the configuration of the 13-hydroxyl, although the individual
triol structures were assigned based on the structure of their
parent epoxyalcohol together with GC-MS and proton NMR
analyses (35).
To develop a method capable of resolving this complex mix-
ture of linoleate triols and to permit analysis by LC-MS, we
adapted our recently reported procedure employing SP-HPLC
of the methyl ester DMP acetonide derivative (35). By substi-
tuting use of the PFB ester in place of the methyl ester, the
analyte becomes amenable to sensitive detection by negative
ion/chemical ionization mass spectrometry (Fig. 4) (36, 37).
The PFB esters are less polar than the corresponding methyl
esters and elute slightly earlier on SP-HPLC, but otherwise the
separations are comparable. Fig. 4A illustrates separation of the
PFB-DMP derivative of triols 1–4 derived from the 9R,10R,13R
epoxyalcohol and detected by LC-MSmonitoring of theM-PFB
ion at m/z 369. The corresponding chromatogram of all eight
triols are shown in Fig. 4B, this mixture being the d4-triols we
prepared from d4-linoleic acid (see “Experimental Proce-
dures”) and detected at 4 atomic mass units higher atm/z 373.
Identification of a Major Esterified Linoleate Triol in Pig
Epidermis—Initial LC-MS analyses of extracts of pig epidermis
taken through the extraction procedure revealed only trace
quantities of free triols (1% of the amounts esterified, Fig. 5A)
and a particularly prominent peak at 16.5 min among the
esterified triols (Fig. 5, B and C). As pH 3 treatment of any
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epoxyalcohols present in the extracts would form a nonspecific
mixture of triols and as the profiles in Fig. 5, B andC, are essen-
tially indistinguishable, this suggests that non-enzymatic
epoxyalcohol hydrolysis contributed little toward these mea-
surements. Although the prominent peak at 16.5 min co-chro-
matographed with triol-3 of our standards, we considered that
further proof of its structurewas required. Accordingly, first we
recorded full scans (m/z 100–700) on the esterified samples,
proving that all peaks corresponding to the triol standards
showed essentially indistinguishable NICI mass spectra with a
major fragment ion atm/z 369 due to loss of the PFB ester (data
not shown). There was sufficient of the major peak from pig
epidermis to allow its detection by HPLC with UV detection
and its UV spectrummatched that of a PFB ester. This peakwas
collected, and after silylation on the free hydroxyl with N,O-
bis(trimethylsilyl)trifluoroacetamide, it was analyzed by
GC-MS in the electron impact mode (Fig. 6). The major triol
from pig epidermis had the same retention time on GC as the
PFB ester DMP TMS ether derivative of the triol-3 standard.
Themass spectra of sample and standard were essentially iden-
tical with diagnostic ions at m/z values of 547 (M  129), 493
(M 147), 461 (M [71Me3SiOH]), 270 (Me3SiO PFB),
227 and 228, 199 (C11 to C18), 181 (PFB), 173 (C13 to C18), 99
(C13 to C18Me3Si), and 73 (Me3Si), thus confirming the
structure as a 9,10,13-trihydroxy-octadecenoate. The mass
spectrum is similar in character and shows the corresponding
fragmentation to the published spectrum of the corresponding
methyl ester derivative (35).
Finally, using a racemic triol-3 standard prepared from
9RS-HPODE and a chiral triol-3 standard prepared from
9S-HPODE, we developed a chiral column HPLC-UV method
for analysis of the stereochemistry of triol-3 as the PFB DMP
derivative (Fig. 7A). The triol-3 from pig epidermis eluted as a
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single peak from the chiral column (Fig. 7B), and when mixed
with racemic standard, it precisely co-chromatographed with
the first triol-3 enantiomer (Fig. 7C). Thus, the prominent
esterified triol of pig epidermiswas unambiguously identified as
9R,10S,13R-trihydroxy-octadec-11E-enoate.
Identification of the Major Esterified Linoleate Triols in
Human Epidermis—Similar to pig epidermis, there are only
trace levels of free fatty acid triol in human epidermis (Fig. 8A).
The epidermis treated with pH 3 or pH 6 gave very similar
profileswithmajor peaks at8min retention time correspond-
ing to 9S,10S,13S-triol (triol-1) and themore prominent peak of
9S,10R,13S-triol (triol-3) eluting at 16 min (Fig. 8, B and C).
Using the methods we developed for steric analysis of the
9,10,13-hydroxyl configuration, we identified the human epi-
dermal triols as exclusively the 9R,10R,13R enantiomer of
triol-1 (Fig. 9, A–C), and the 9R,10S,13R enantiomer of triol-3
(Fig. 9,D–F). The relative proportions of the linoleate triols 1, 2,
3, and 4 esterified in human epidermis averaged 33,1, 63, and
3%, respectively, in three analyses.
Quantification of 9-HODE, Epoxyalcohol, Triols, and Fatty
Acids in Porcine and Human Epidermis—The content of the
three oxidation products quantified in porcine and human epi-
dermis are given in Tables 1 and 2, respectively. Porcine epider-
mis contained 5–10-fold higher amounts of esterified epoxyal-
cohol and triol-3 compared with human epidermis, along with
quantitatively similar levels of 9-HODE. Representative chro-
matograms from the quantitative analyses of human epidermal
esterified 9-HODE, epoxyalcohol, and triol-3 are illustrated in
Fig. 10.
Unlike the epoxyalcohol and triols that are present almost
entirely in esterified form, about half the HODEs measured in
human epidermis are present as the free acid, non-esterified
(supplemental Fig. S3). Therefore, the quantitative analysis of
9-HODE in Fig. 10A (the KOH-treated extractable lipids) rep-
resents free plus esterifiedHODEs; 9-HODEPFBester eluted as
the distinct peak at10.5 min, about 0.2 min before the d4–9-
HODE standard on this SP-HPLC system; otherHODE isomers
eluted in them/z 295 (d0) channel, with 13-HODE at8.5 min
being prominent in all samples. Chiral HPLC analysis indicated
the 9-HODE was predominantly 9R in configuration (supple-
mental Fig. S4). The presence of 9R-HODE along with 13S-
HODEwas reported in human psoriatic scales (38); 13S-HODE
was identified as themore prominent product formed in homo-
genates of normal skin (39, 40).
The epoxyalcohol of human skin was almost exclusively
esterified (Fig. 10B), with levels of the free products giving
d0/d4 ratios similar to the d4 standard (supplemental Fig. S5).
Fig 10B also illustrates the retention time of the later-eluting
cis-epoxy isomer, 9R,10S-cis-epoxy313R-hydroxy-11E-octeno-
ate. Enzymatic hydrolysis of this cis-epoxide would be expected
to give rise to predominantly triol-1 as hydrolysis product, but it
consistently appeared as a small peak relative to the trans-ep-
oxide and apparently insufficient to account for the promi-
nence of esterified triol-1 in the human epidermal extracts (cf.
Fig. 8, B and C). Chiral HPLC analysis of the major trans-ep-
oxyalcohol in three human samples gave values of 88, 97, and
98% of the 9R,10R-trans-epoxy-13R-hydroxy enantiomer (sup-
plemental Fig. S6).
Assay of triol-3 in human epidermis confirmed its occur-
rence along with about half the amount of triol-1 (Fig. 10C).
Similar to its epoxyalcohol precursor, the levels of free (non-
esterified) triol-3were below the limit of detection (supplemen-
tal Fig. S7). For comparison with the epidermal content of
oxidized linoleate products, esterified LA, -LNA, and AA con-
centrations were quantified as 9800 (range 8500–12,800)g/g,
1523 (1200–1800) g/g, and 1423 (1000–2050) g/g, respec-
tively. Remarkably, the oxidized products are present in human
epidermis in 0.01% of the abundance of intact linoleate (for
epoxyalcohol and triol) and 0.06% relative abundance (for
9-HODE and 13-HODE). Nonetheless, the oxidized products
are chiral, indicating their enzymatic origin and genetic evi-
dence confirms the importance of their biosynthesis in the
mammalian epidermal barrier.
Examining an Alternative Route to Forming Protein-bound
Ceramide—As noted in the Introduction, the ultimate struc-
tural consequence of the oxidations in the LOX pathway of the
epidermal barrier is formation of protein-bound ceramide and
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the CLE. The conventional view, as we proposed, is that oxida-
tion of the linoleate esterified in ceramide-EOS facilitates hy-
drolysis of the ester bond, releasing ceramide-OS for coupling
to protein via its free -hydroxyl (Scheme 2, conventional
route) (8). That theOS ceramide is directly coupled to protein is
supported bymass spectrometric evidence of ceramide-peptide
conjugates isolated from epidermal proteins and by the cou-
pling of OS surrogates to protein via transglutaminase (41, 42).
Nonetheless, these experiments do not fully account for the
total protein-bound ceramide (41, 43), and the oxidation of
linoleate to triol has the potential for protein binding via a
hydroxyl of the linoleate triol, obviating the need for the (so far
unidentified) esterase cleavage of the oxidized linoleate
(Scheme 2, alternative route).
To test for protein-bound triols, pig epidermis was extracted
several times with CHCl3/MeOH, including soaking overnight
in the solvents. Thewashed protein pellet was then treatedwith
KOHovernight to hydrolyze ester bonds and to release protein-
bound fatty acids. An aliquot of d4-triols was then added, and
the samples were taken through the usual extraction and
derivatization procedures for LC-MS analysis of the PFB-DMP
triols. A sample of the solvent-extracted lipids (with added
d4-triol mixture) was analyzed in parallel. In contrast to the
strikingly prominent peak of triol-3 recovered from the soluble
esters, the pattern of triols released from the protein pellet was
largely a nonspecific mixture of all eight triols with a slight
preponderance of triol-3 (supplemental Fig. S8). Furthermore,
there was greater than 10-fold excess of triol-3 esterified in the
CHCl3/MeOH-soluble lipids compared with the amounts
recovered from the protein pellet. We conclude that the triol-3
could likely arise from lipid retained in the protein pellet. The
rest of themixture is a non-selective hydrolysis of RRR and RRS
epoxyalcohols (Fig. 4, top), the latter not an enzymatic product,
and therefore we deduce that the mixture reflects a low level of
non-enzymatic oxidation and is not a significant participant in
the binding of ceramides to protein.
Discussion
Detection of Esterified Triols and Their Significance—Our
findings establish the existence of trace levels of esterified lino-
leate triols in human and pig epidermis, which is consistent
with their obligatory role in forming the intact skin water bar-
rier. Despite the tiny percentage (0.1%) compared with the
esterified linoleate itself, the abundance of specific isomers, and
particularly the chiral analyses, leaves no doubt that these lino-
leate triols derive from specific enzymatic oxidation. Their pure
9R chirality is characteristic of 12R-LOX oxidation of linoleate,
and the pure 13R chiralitymatches the product of eLOX3 trans-
formation of 9R-HPODE to the epoxyalcohol 9R,10R-trans-ep-
oxy-13R-hydroxy-octadec-11E-enoate (8). We should empha-
size that only trace levels of these specific triols are to be
expected according to our hypothesis of their role in differen-
tiation of the skin barrier. By the disrupting effect on the lipid
environment, it is proposed that the polar trihydroxy-linoleates
facilitate the actions of an esterase that cleaves the triol (and
probably facilitating the hydrolysis of other EOS species, too) to
produce free OS for covalent coupling to protein and con-
struction of the CLE (Fig. 11). This is another example of the
well accepted line of evidence that oxidation of polyunsaturated
esters leads to their preferential cleavage from lipidmembranes
(44–47). Therefore, the oxidized linoleates are intermediates
in ongoing transformations that lead to their removal from the
membrane, and accordingly, the detection of trace levels is con-
sistent with their obligatory role in barrier function.
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Specific Triol Structures and Their Mechanism of
Formation—It is well established that non-enzymatic hydroly-
sis of the eLOX3-derived allylic epoxyalcohol produces a mix-
ture of four triols formed by attack of water at the 10- and
12-carbons, the four varying in relative abundance from10 to
60% (Fig. 3A) (cf. Refs. 35, 48, 49). By contrast, pig epidermis
contains only one prominent triol esterified in the lipids,
accounting for around 90% of the total. The same isomer is also
the most abundant in human epidermis. The major esterified
triol we identify is the expected product of a specific SN2 hydro-
lysis that reverses the configuration at C-10 of its 9R,10R,13R
epoxyalcohol precursor, giving the 9R,10S,13R-trihydroxy-oc-
tadec-11E-enoate. In human epidermis this is accompanied by
lesser amounts of the 10R isomer. A potential explanation for
the occurrence of the second triol (9R,10R,13R) in human epi-
dermis would be the presence of a 9R,10S-cis-epoxy-13R-hy-
droxy precursor in the lipids, the SN2 hydrolysis of whichwould
form the RRR triol. However, the peak of this cis-epoxide
detectable in our LC-MS analyses is minor (Fig. 10B) and
appears insufficient to account for the relative prominence of
the RRR triol. Our studies with metabolism of 9R-HPODE by
recombinant human eLOX3 support formation of only the
9R,10R-trans-epoxy-13R-hydroxy epoxyalcohol (8). To the
best of our knowledge, there is no precedent for non-enzymatic
hydrolysis in which shielding might eliminate the attack of
water at C-12, and therefore involvement of epoxide hydro-
lase(s) is the most straightforward explanation for occurrence
of the specific linoleate triols in the esterified lipids.
Possible Involvement of Epoxide Hydrolase—Hydrolysis cata-
lyzed by an epoxide hydrolase would be specific, with pure SN2
attack on the allylic 10-carbon, thus producing the major triol
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(Table 2).
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we find esterified in pig and human epidermis. So far, no epox-
ide hydrolase has been tested with substrates directly relevant
to our study. In terms of known catalytic activities, mammalian
soluble epoxide hydrolase (sEH, EPHX2) is a potential candi-
date as it efficiently hydrolyzes trans-epoxides, and the trans-
epoxides of arachidonic acid-derived hepoxilins are good sub-
strates (50, 51). In the same gene family is also the microsomal
epoxide hydrolase (mEH, EPHX1), which has specificity for
cis-epoxides (52) and therefore appears an unlikely candidate.
For epoxide hydrolase 3 (EPHX3, ABHD9), so far high catalytic
activity is demonstrated for non-allylic cis-epoxy-fatty acids,
epoxy-stearate, and epoxy-eicosatrienoic acids (53); the suita-
ble catalytic activity of EPHX3 on the allylic trans-epoxyal-
cohols remains an open issue. Currently, there is no infor-
mation on the substrate specificities of the other two
putative epoxide hydrolases, epoxide hydrolase 4 (EPHX4 or
ABHD7) and MEST/Peg1 (paternally expressed gene-1) (52,
54), nor on several members of the more distantly related
mammalian --hydrolases implicated as acyltransferases
or hydratases (54).
Expression in skin or epidermis, as far as established, is suit-
able for sEH (55) and EPHX3 (53) and unknown/not investi-
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TABLE 1
Quantitative analysis of epidermal 9-HODE, 9-epoxyalcohol, and triol-3 in pig epidermis
Epidermal content
(per g wet weight of epidermis) 9-HODE 9,10-trans-Epoxyalcohola Triol-3
nmol/g, n 3 (range) 43.7 (39.1–46.0) 23.4 (21.0–27.7) 32.7 (30.6–34.4)
g/g, n 3 (range) 13.1 (11.5–14.2) 7.3 (6.6–8.6) 10.8 (10.1–11.3)
a The epoxyalcohol assayed is 9R,10R-trans-epoxy-13R-hydroxy-octadec-11E-enoate.
TABLE 2
Quantitative analyses of epidermal 9-HODE, 9-epoxyalcohol, and triol-3 in human epidermis
Epidermal content
(per g wet weight of epidermis) 9-HODE 9,10-trans-Epoxyalcohola Triol-3
nmol/g, n 6 (range) 28.8 (20.9–37.1) 4.1 (1.7–5.4) 3.1 (2.1–3.8)
g/g, n 6 (range) 8.5 (6.1–10.9) 1.2 (0.5–1.7) 1.0 (0.7–1.2)
a The epoxyalcohol assayed is 9R,10R-trans-epoxy-13R-hydroxy-octadec-11E-enoate.
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gated for most other candidates. EPHX3 was detected as a pro-
tein highly expressed in human outer epidermis (57) and
identified in an ichthyosis gene cluster by comparative mRNA
coexpression (58). Despite such indications, inactivating muta-
tion of the murine and human EPHX3 gene give no reported
skin phenotypes (59) and similarly for knockouts of mEH (60),
sEH (61), and MEST/peg1 (62). So based on the information
currently available, it appears that the current murine gene
knock outs do not target the appropriate epoxide hydrolase, or
alternatively theremay be redundancy in the epoxide hydrolase
function in the epidermis.
Product Polarity as the Key Feature of Linoleate Oxidation—
We surmise the primary role of the linoleate triols in barrier
formation is to induce disruption of the membrane lipids, in
turn facilitating the ester hydrolysis that provides OS ceramide
for construction of the CLE. The actions of 12R-LOX convert
the relatively non-polar linoleate to the 9-hydroperoxide with a
significant increase in polarity of the oxidized linoleate ester.
Why then does eLOX3 gene knock-out (Aloxe3/) result in a
significant skin phenotype? The further action of eLOX3 trans-
forms the 9-hydroperoxide to an epoxyalcohol, which does not
itself induce a major increase in polarity, yet eLOX3 gene dele-
tion is associatedwith a strong phenotype.We conclude it is the
further transformation of epoxyalcohol to trihydroxy-linoleate
that the eLOX3 reaction permits that explains the significant
phenotypewhenAloxe3 is deleted. TheAloxe3/phenotype is
slightly less severe than the 12R-LOX knock out (7), and one
might anticipate that deletion of the epoxide hydrolase(s)
responsible for linoleate triol synthesis to have a similar
phenotype.
History of Linoleate Oxidations and the Epidermal Barrier—
In the mid-1980s Nugteren et al. (63) reported the metabolism
of [1-14C]linoleic acid applied topically to the back skin of EFA-
deficient rats. Identified among the radiolabeled products were
what they termed “polyoxyacyl” ceramides, the structures rep-
resented as a mixture of 9,10,11-, 9,10,13-, 9,12,13-, and
11,12,13-trihydroxy-linoleates esterified to EOS ceramide. The
authors concluded that formation of these derivatives is impor-
tant for the integrity of the epidermal water barrier, and in a
subsequent review they sumup as follows: “Currently, however,
we believe that it is the polyoxyacylceramide derivative of AC
(acylceramide or EOS), recently discovered by ourselves, which
is key to the correct formation or maintenance of the permea-
bility barrier in the compactum region. How it achieves this
remains amystery and is currently under investigation” (64). As
it happened, no new insights were forthcoming, and further-
more, others discounted the findings of oxidized linoleate in the
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epidermal ceramides as non-enzymatic artifacts (65). Nothing
more has appeared on the subject until our characterizations of
specific oxidation of linoleate in the epidermal EOS (8) and
extended now to identify the very specific LOX-derived linole-
ate triols. Clearly, our findings support the early work and con-
clusions ofNugteren et al. (63) and provide themissing concep-
tualmodel that links the EFAmetabolism to construction of the
epidermal water barrier.
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The Precise Structures and Stereochemistry of Trihydroxy-Linoleates Esterified in Human 
and Porcine Epidermis and Their Significance in Skin Barrier Function: 
IMPLICATION OF AN EPOXIDE HYDROLASE IN THE TRANSFORMATIONS OF 
LINOLEATE 
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Valerie B. O’Donnell, and Alan R. Brash 
 
 
Fig. S1. Analytical procedures for the identification of free and esterified products in epidermis 
 
Fig. S2. Analytical procedures for the quantitation of free and esterified 9-HODE, epoxyalcohol 
  (EpOH) and triols in epidermis. 
 
Fig. S3   LC-MS analysis of the free (non-esterified) 9-HODE in human epidermis 
 
Fig. S4    Chiral analysis of 9-HODE in human epidermis 
 
Fig. S5 LC-MS analysis of the free (non-esterified) linoleate epoxyalcohol in human epidermis 
 
Fig. S6 Chiral column LC-MS analysis of the stereochemistry of the major epoxyalcohol 
esterified in human epidermis 
 
Fig. S7 LC-MS analysis of the free (non-esterified) linoleate triol in human epidermis 
 
Fig. S8 The profile of protein-bound triols in pig epidermis 
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Figure S1. Analysis of free and esterified products in epidermis 
Purification scheme for analysis of triols in human and pig epidermis. After extraction from 
epidermis using CHCl3/MeOH and open-bed silica fractionation, separate aliquots were analyzed 
for free triols (left-hand arm) and esterified triols (middle and right-hand arms). Esterified triols 
were released by alkaline hydrolysis overnight. After Bligh & Dyer partitioning to remove 
neutral and non-polar lipids in the CHCl3 phase, samples were either extracted on an Oasis HLB 
cartridge at pH 6 (to avoid hydrolysis of epoxyalcohols to triols), or after standing at room 
temperature at pH 3 for 30 min to allow acid hydrolysis of epoxyalcohols. The recovered triols 
were converted to the PFB DMP derivative and analyzed by HPLC, GC-MS and LC-MS. 
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Figure S2. Quantitation of free and esterified 9-HODE, epoxyalcohol (EpOH) and triols in 
epidermis. 
After the initial extraction and open-bed silica column, free fatty acid products are taken through 
the left-hand arm of the scheme; Bligh and Dyer partition using 0.1 M K2HPO4 as the aqueous 
phase allows removal of neutral and non-polar lipids in the CHCl3 while retaining the ionized 
fatty acids in the aqueous layer; the free acids in the mildly alkaline solution are subsequently 
retained on an Oasis HLB cartridge, eluted with EtOAc and derivatized for LC-MS analyses. The 
right-hand arm follows a similar protocol after esterified products are released by KOH treatment 
overnight. 
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Fig S3: LC-MS analysis of the free (non-esterified) 9-HODE in human epidermis 
The analyses used a Thomson Scientific Advantage 5µ silica column (25 x 0.46 cm), with a 
solvent of solvent hexane/IPA (100:0.5 v/v), flow rate 1 ml/min, and LC-MS detection of the 
PFB ester (M – PFB ion) at m/z 295 (do) and 299 (d4). The early peak at ~6.6 min in the m/z 
295 channel (d0) is 13-HODE. 
The chromatogram is representative of the epidermis from three different subjects.  
 
 
 
Fig. S4: Chiral HPLC analysis of 9-HODE from human epidermis 
The analyses used a Chiralcel OD-H column (25 x 0.46 cm), a solvent of hexane/IPA (100:5 v/v) 
and a flow rate of 1 ml/min with UV-detection of the conjugated diene chromophore at 235 nm. 
Epidermis from three different individuals were analyzed: the percentage of 9R enantiomer was 
79.8%, 85.5% (shown above), and 85.7%. 
The analyses were conducted on the total 9-HODE (free plus esterified). 
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Fig. S5: LC-MS analysis of the free (non-esterified) epoxyalcohol in human epidermis 
 
The ratio of d0/d4 epoxyalcohol in this analysis is 0.0025, corresponding to only ~2% of the 
esterified epoxyalcohol. 
(By comparison, the d0/d4 ratio measured for esterified epoxyalcohol is approximately 0.5, Fig. 
10B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig S6: Chiral column LC-MS analysis of the chirality of the major epoxyalcohol esterified 
in human epidermis as 9R,10R-trans-epoxy-13R-hydroxy-octadec-11E-enoate.  
The analysis used a Chiralcel OJ column (25 x 0.46 cm), a solvent of hexane/IPA (100:10 v/v), a 
flow rate 1 ml/min, with LC-MS detection of PFB ester monitoring the [M – PFB]- ion at m/z 
311. 
Epidermis from three different individuals were analyzed: the percentage of RRR enantiomer was 
88%, 97% (shown above), and 98%. 
 
 
 
 
 
 
  
C:\XCalibur\...\Human_068_chiral 3/21/2016 1:33:59 PM
RT: 0.00 - 12.00 SM: 7B
0 1 2 3 4 5 6 7 8 9 10 11
0
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
ecnadnubA evitale
R
NL:
2.14E5
m/z= 
310.50-
311.50  
MS 
Human_06
8_chiral
m/z 311 
0
Retention time (min)
2 4 6 8 10 12
SSS
enantiomer
RRR
enantiomer
R
el
at
iv
e 
Ab
un
da
nc
e
RT: 0.00 - 12.00 SM: 7B
0 1 2 3 4 5 6 7 8 9 10 11
0
10
20
30
40
50
60
70
80
90
100
0
10
20
30
40
50
60
70
80
90
100
MA: 10350
MA: 4033732
NL: 5.23E4
m/z= 310.50-311.50  
MS Human_058
NL: 3.38E5
m/z= 314.50-315.50 
F: - c APCI Q1MS 
[310.500-311.500, 
314.500-315.500]  
MS Human_058
0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 4.5 5.0 5.5 6.0 6.5 7.0 7.5 8.0 8.5 9.0 9.5
0 1 2
Retention time (min)
3 4 5 6 7 98
R
el
at
iv
e 
Ab
un
da
nc
e
m/z 315 (d4)
m/z 311 (d0)
d4-epoxyalcohol
d0/d4 ratio
= 0.0025
d0
 6 
 
Fig. S7     LC-MS analysis of the free (non-esterified) linoleate triols in human epidermis 
  The samples were analyzed for free (non-esterified) linoleate triols using the 
method summarized in Fig 2B of the main text. Detection of the PFB ester, DMP derivative for 
unlabeled triols (m/z 369) and the d4-triol-3 and d4-triol-4 detected at m/z 373. 
(By comparison, the d0/d4 ratio measured for esterified triol-3 is approximately 220 parts per 
thousand, Fig. 10C). 
The peak at ~ 7.7 min below in the d0 channel is a contaminant of pinellic acid (triol-2) used to 
check the derivatization. 
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Fig. S8 (A, top) The profile of protein-bound triols in pig epidermis compared with 
CHCl3/MeOH soluble esterified triols (B, below). 
 Normal-phase LC-MS analysis of the PFB ester DMP acetonide derivative using a 
Thomson Advantage 5 µ silica column with a solvent of hexane/IPA (100:1, v/v), a 
flow rate of 1 ml/min with monitoring of the [M – PFB]- ion at m/z 369. 
         The numbers correspond to the linoleate triols shown in Fig. 3 of the main text. The 
intensity of the major esterified triol-3 (lower panel) was over 10-fold higher than the 
corresponding protein-bound triol.  
         We conclude that non-specific oxidation accounts for these comparatively low levels of 
protein bound triols and that coupling of EOS-triol to protein (the a hydroxyl on the 
triol moiety) is of minor consequence compared to protein binding via the omega-OH 
of ceramide OS. 
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